A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
posted on
Oct 26, 2020 08:15AM
https://www.resverlogix.com/investors/news.html?article=682
CALGARY, Alberta, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that its late-stage clinical candidate, apabetalone, has been prominently featured in a recent article, titled: “Protein-driven mechanism of multiorgan damage in COVID-19”, in the peer-reviewed journal Medicine in Drug Discovery.
The publication can be viewed using the following LINK.
“Significantly, this is the second peer-reviewed article to highlight apabetalone, the link between BET proteins – the exact target of apabetalone – and COVID-19,” said Donald McCaffrey, President and CEO of Resverlogix. “Of the many therapies discussed in the article, apabetalone is highlighted as a potential treatment for multiorgan damage caused by COVID-19 due to its safety profile and target. The publication suggests the case for apabetalone as a safe, potential COVID-19 therapeutic. We look forward to providing additional data on the effects of apabetalone on COVID-19 infection in our upcoming American Heart Association presentation on November 13, 2020.”
Publication Highlights and Discussions Include:
Program Update:
As previously announced, an article published on March 23, 2020 revealed the interaction between SARS-CoV-2 (COVID-19) protein E with BET proteins. Following this finding, Resverlogix put out a call for collaborations, resulting in multiple partnerships, and in parallel initiated preclinical research efforts in-house to further characterize and investigate apabetalone efficacy against COVID-19 infection. From our own studies we have found that beyond the role of BET proteins in viral replication, apabetalone was shown to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus to enter human cells. Apabetalone is an investigational, phase 3 clinical candidate with safety data in more than 4,000 subjects. Additional details from these multiple programs are expected to be presented in the coming few months.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.
BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on:
For further information please contact:
Investor Relations
Email: [email protected]
Phone: 403-254-9252
Or visit our website: www.resverlogix.com